pharmaphorum Podcast

• Patients as active consumers of care: AI-driven personalisation in pharma marketing

  Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bill Grambley, CEO of AllazoHealth, for a conversation on leveraging AI for marketing, as well as medication initiation and adherence. Grambley discusses how AI can be leveraged to create highly personalised patient engagement strategies, tailored to individual needs and preferences, as well as the technology can be used to identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes. The conversation touches upon the ethical implications of using AI to collect and analyse patient data, and how pharmaceutical companies are ensuring patient data privacy and security while leveraging AI to improve outcomes, in addition to the regulatory landscape and the future horizon. You can listen to episode 175a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  24:02
• Driving the drug discovery pipeline: The value of organ-on-a-chip MPS

  In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs permit is a screening of new drugs, of whatever entity – chemical or biological – to better predict how they will behave when put into a patient, says Kostriezewski. From metabolic to neurological diseases, as well as oncological – the applicability of organ-on-a-chip technologies is wide ranging, and regulators have been taking a more active role in trying to understand their role and value, and thereby validate their contextual usage at a future point. Nonetheless, already data is accepted today using this new approach, explains Kostriezewski, providing further insights on the landscape as market adoption continues to grow globally. You can listen to episode 174a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  18:42
• Intelligent regulatory compliance and improved patient outcomes

  Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory compliance. For both pharma and medical device companies, time and bandwidth are the number one challenge RA professionals face, closely followed by costs and budgetary pressures (the latter being a more pronounced concern for medical device companies). And, as the medical device sector responds to rising demands internationally around device identification, traceability, safety, and surveillance – designed to reinforce product quality and safety – companies have a chance to expedite their preparations, by looking to the adjacent pharma industry for lessons still being learned. Veluchamy dives into the details and explains what all these endeavours ultimately mean for patients. You can listen to episode 173a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  15:10
• Prevention for a healthier, more productive society

  In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possibilities from the panel discussion. Prevention is increasingly seen as contributing to a healthier and more productive society. But, as healthcare resources are stretched and medical science is accelerating, the question remains: how do we make prevention a reality? Encouragingly, healthcare systems are increasingly seeing the health, social, and economic benefits of prevention when it is delivered in an evidence-based way. You can listen to episode 172a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  15:13
• Safeguarding the pharmaceutical supply chain

  As we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters. Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency protocols and drug reserves to be in place in the worst-case scenarios, and permits plants to return to full operation as speedily as possible. And this is where Aravo, a third-party management software solutions company, comes in, operating at three macro levels: life cycle management, the due diligence process, and providing unified visibility into all this information. Alms talks through the different scenarios and ways of approach to best safeguard the pharmaceutical supply chain, and explains what should be top of mind for chief risk officers when each extreme weather season arrives. You can listen to episode 171a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  13:37

Altri podcast di Scienze

Podcast di tendenza in Scienze

Su pharmaphorum Podcast